Verition Fund Management LLC
Position in SLS — SELLAS Life Sciences Group, Inc.
CIK 1454027
GREENWICH, CT
Position in SLS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$0
-$51,868 QoQ
Shares Held
0
-100.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
3 quarters on record
Derivatives in SLS
reported options exposure · as of Jun 30, 2026CallValue
$832,464
CallShares
56,400
PutValue
$916,596
PutShares
62,100
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026Verition Fund Management LLC holds $156,064,619 across 65 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TECH |
BIO-TECHNE Corp
|
438,746 | $30,997,404 | |
| 2 | 159,256 | $21,138,048 | |||
| 3 | ABVX |
Abivax S.A.
|
105,791 | $14,097,708 | |
| 4 | IDYA |
IDEAYA Biosciences, Inc.
|
184,054 | $6,859,692 | |
| 5 | SNDX |
Syndax Pharmaceuticals Inc
|
304,939 | $6,665,966 | |
| 6 | MRVI |
Maravai Lifesciences Holdings, Inc.
|
777,738 | $4,853,085 | |
| 7 | CYTK |
Cytokinetics Inc
|
54,889 | $4,675,993 | |
| 8 | RPRX |
Royalty Pharma plc
|
75,000 | $4,205,250 |
All Filings in SLS
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $832,464 | 56,400 | Call | Sole | 2026-08-14 | |
| 2026-06-30 | $916,596 | 62,100 | Put | Sole | 2026-08-14 | |
| 2026-03-31 | $255,069 | 60,300 | Put | Sole | 2026-05-15 | |
| 2026-03-31 | $51,868 | 12,262 | Shares | Sole | 2026-05-15 | |
| 2026-03-31 | $421,731 | 99,700 | Call | Sole | 2026-05-15 | |
| 2025-12-31 | $49,010 | 13,000 | Call | Sole | 2026-02-13 | |
| 2025-12-31 | $73,515 | 19,500 | Put | Sole | 2026-02-13 | |
| No filing history on record for this holder in this stock. | ||||||